FP7Индивидуална стипендия2009–2010

AMYLOIDINTERMEDIATE · The structural and dynamical ensemble of an amyloidogenic intermediate

7РП — „Хора“ (Действия „Мария Кюри“)

Период
2009-07-01 → 2010-02-28
Финансиране от ЕС
171 868 €
Участници
1
Схема
MC-IEF

Линиите свързват координатора с партньорите.

Накратко на български

Протеините и механизмите за тяхната разтворимост се анализират чрез модел с протеин от плодова мушка. Разбирането на тези процеси помага да се разбере защо някои протеини се събират в агрегати, свързани с болести като Алцхаймер и диабет тип II.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

The structural and dynamical ensemble of an amyloidogenic intermediate

The majority of proteins have evolved to adopt distinctive and well-defined functional states under physiological conditions, either as monomers or as complexes. The structures corresponding to these states are encoded in the sequence as is the crucial ability of the molecules to remain soluble within the crowded cellular environment. It is increasingly evident, however, that even under physiological conditions the aggregated states of proteins, such as the highly ordered amyloid form, can be thermodynamically more stable than native states, indicating that kinetic factors are of key importance in enabling protein homeostasis to be maintained. Proteins in vivo only rarely convert into aberrant aggregated states, such as those associated with pathological conditions such as Alzheimer's disease and type II diabetes, despite their inherent tendency to do so in vitro. In the present research, we used a combination of NMR experiments and molecular dynamics simulations to identify the characteristic features of the free energy landscapes that enable the majority of the proteins to avoid aggregation under physiological conditions. We chose for this scope the acylphosphatase from Drosophila melanogaster (AcPDro2) as this is a particularly well-suited system for investigating the molecular strategies used by living systems for the maintenance of protein solubility. AcPDro2 in its native state is a globular and monomeric protein with a structure consisting of five ß-strands (S1-S5), which form a single ß-sheet, and two a-helices (H1 and H2) that lie adjacent to this ß-sheet. The importance that subtle intrinsic factors play in enabling this protein to remain soluble is clearly shown by the fact that a very low concentration (5 % v/v) of trifluoroethanol (TFE) is sufficient to induce rapid formation of amyloid fibrils although the protein still populates a highly native-like conformational ensemble before aggregation occurs. Indeed, under these conditions, the hydrodynamic radius, intrinsic fluorescence, secondary structure content and enzymatic activity of AcPDro2 in its monomeric state are indistinguishable those of the protein in the absence of TFE, where the propensity of AcPDro2 to aggregate is extremely low. Moreover, within the experimental error, AcPDro2 has the same thermodynamic stability (i.e. the same free energy of unfolding, ?GU-F) in the presence and absence of 5 % v/v TFE. By contrast to AcPDro2, most folded proteins aggregate in the presence of much higher concentrations of TFE (15-30 %) where a significant portion of the molecules are unfolded or strongly destabilised. We could determine a series of energy landscapes of AcPDro2 thus analysing the differences in the structures, dynamics and energy surfaces of the protein in its soluble state or in situations where it aggregates. The study identifies the nature of the energy barriers that under normal physiological conditions prevent the protein ensemble from populating dangerous aggregation-prone states. We found that such states, although similar to the native conformation, have altered surface charge distribution, alternative topologies of the ß-sheet region and modified solvent exposure of hydrophobic surfaces and aggregation prone regions of the sequence. The identified barriers allow the protein to undergo functional dynamics while remaining soluble and without a significant risk of misfolding and aggregation into non-functional and potentially toxic species.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Proteins and peptides have a generic tendency to convert from their soluble states into well-organized aggregates characterized by a fibrillar morphology and an extended cross-beta structure. Such transitions can give rise to over 40 pathological conditions ranging from neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, polyQ disease, to systemic amyloidoses, including light chain amyloidosis and hemodyalisis-related amyloidosis. Unveiling the origins of amyloid disorders is one of the top scientific challenges. It is clear that a better understanding of the molecular mechanisms of protein and peptide aggregation into amyloid fibrils will allow optimal therapeutic strategies and the development of better drugs to combat these disorders. Nevertheless, despite the huge efforts of the scientific community, the molecular determinants underlying these processes are still largely obscure. The aim of the present project is to determine, at an atomic level, the structural and dynamical ensemble of the amyloidogenic intermediate of a novel Acilphosphatase, the AcPDro2. This protein represents a prototype of for studying the aggregation via native-like conditions, a major aggregation pathway in vivo. The project will be performed in the lab of prof. C.M. Dobson (University of Cambridge) and will be based on a multidisciplinary approach of experiments (basically solution-NMR) and molecular simulations to characterize the conformational ensembles adopted along the AcPDro2 aggregation pathway. This study will provide the atomic description of the molecular determinants of AcPDro2 aggregation into amyloid structures. Moreover, an appealing part of the project will focus on the mode of actions of a small ligand, the phosphate, which is able to inhibit the AcPDro2 aggregation. This determination will represent an unprecedented information with implications in the field of drug design for targeting amyloid-linked diseases.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз